SEC Form 4 · accession 0000950138-17-000616
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Meredith B Fischer
Officer — Chief Public Affairs Officer
Period of report
Aug 30, 2017
Accepted (ET)
Sep 1, 2017 · 8:57 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Aug 30, 2017 | P | 1,280 | $39.6291 | A | 28,708 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $39.60 to $39.64, inclusive. Ms. Fischer will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range.
- F2Includes 142 shares acquired on June 30, 2017 under the Mallinckrodt employee stock purchase plan.